Compare HOWL & GNLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | HOWL | GNLX |
|---|---|---|
| Founded | 2017 | 2001 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 48.1M | 123.1M |
| IPO Year | 2021 | 2022 |
| Metric | HOWL | GNLX |
|---|---|---|
| Price | $0.96 | $2.60 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 4 |
| Target Price | $5.00 | ★ $17.25 |
| AVG Volume (30 Days) | ★ 10.4M | 360.7K |
| Earning Date | 05-05-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 18.40 | 9.47 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $8,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.27 | $2.29 |
| 52 Week High | $2.23 | $8.54 |
| Indicator | HOWL | GNLX |
|---|---|---|
| Relative Strength Index (RSI) | 82.17 | 43.74 |
| Support Level | $0.80 | $2.33 |
| Resistance Level | $1.17 | $2.98 |
| Average True Range (ATR) | 0.07 | 0.17 |
| MACD | 0.04 | -0.00 |
| Stochastic Oscillator | 89.45 | 17.23 |
Werewolf Therapeutics Inc is a biopharmaceutical company pioneering the development of therapeutics engineered to stimulate the body's immune system for the treatment of cancer and other immune-mediated conditions. It is leveraging the proprietary PREDATOR platform to design conditionally activated molecules that stimulate both adaptive and innate immunity with the goal of addressing the limitations of conventional proinflammatory immune therapies. It has one reportable segment, which focuses on the discovery and development of cancer therapeutics.
Genelux Corp is a late-stage biopharmaceutical firm focused on developing oncolytic viral immunotherapies for cancer. Its pipeline includes clinical and preclinical candidates designed to target tumor cells and stimulate an immune response against tumor-specific antigens. The company is focused on the development of next-generation oncolytic viral immunotherapies that are designed to generate a personalized multi-prong attack to overwhelm a tumor's sophisticated defense mechanisms.